Onconic Therapeutics

What Onconic Therapeutics does

Onconic Therapeutics Co., Ltd. is a Seoul, South Korea-based clinical-stage biopharmaceutical company founded in May 2020, listed on KOSDAQ under ticker 476060 since December 2024. The company specializes in the research and development of innovative cancer treatments and gastrointestinal therapies, operating across two therapeutic platforms: next-generation P-CAB (Potassium-Competitive Acid Blocker) chemistry for gastric acid-related diseases, and PARP/tankyrase dual-targeting inhibitors for oncology. Its lead commercial assets are JAQBO 20mg tablets (film-coated and orally disintegrating forms of Zastaprazan citrate), marketed in South Korea for erosive GERD and gastric ulcer, while its lead pipeline asset OCN-201 (JPI-547), a second-generation PARP/tankyrase dual inhibitor with FDA Orphan Drug Designation in pancreatic cancer, is in Phase 1b development.

The company's business model combines Korean domestic product sales of JAQBO through pharmacy distribution channels with international out-licensing of drug candidates. The model is anchored on upfront and milestone payments from partners rather than full vertical commercialization. The most material disclosed transaction is the $127.5M licensing deal for Zastaprazan to a Chinese pharmaceutical partner signed in March 2023, alongside participation at BIO USA 2026 to pursue additional global partnerships, licensing deals and CDMO manufacturing contracts. Customer segments are split between South Korean GI patients (via retail pharmacy), cancer patients in pipeline indications (via future partners), and global pharmaceutical partners seeking differentiated mechanisms.

Onconic is led by CEO John Kim (PhD), CFO Jongkil Shin (MBA, Dartmouth Tuck) and CSO Hyunju Cha (PhD), with the leadership team carrying prior experience at Biogen, Boehringer-Ingelheim, LG Chem, Hanmi Pharmaceuticals, Crystalgenomics, Max-Planck-Institut and Ernst & Young. The company is targeting at least two new drug approvals within three years, and the KOSDAQ listing, the $19.9M 2022 funding round from Korean investors, and the company-managed pipeline of Phase 3 (P-CAB) and Phase 1b (PARP/TNKS) clinical programs all support a growth-oriented, partnership-driven commercialization strategy rather than fully integrated commercialization.

Name

Onconic Therapeutics

Legal name

온코닉테라퓨틱스 주식회사

Website

https://onconic.co.kr

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Seoul-based clinical-stage biopharmaceutical company developing next-generation P-CAB therapy for GERD/gastric ulcers and PARP/tankyrase dual inhibitors for cancer, monetizing through Korean product sales and international out-licensing deals.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Oncology drug development
• Gastrointestinal therapeutics
• Pharmaceutical licensing
• Biopharmaceutical R&D
• Acid blocker therapy

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Drug Licensing: Licensing out drug candidates to international partners for upfront payments and milestone payments. Example: GERD drug candidate licensed to China for $127.5 million.
2. Pharmaceutical Product Sales: Commercialization of approved drugs including JAQBO (Zastaprazan citrate) for erosive GERD and gastric ulcer treatment. Revenue from product sales through pharmacy distribution channels in South Korea.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Onconic Therapeutics researches, develops, and commercializes pharmaceutical drugs focused on two therapeutic areas: next-generation P-CAB (Potassium-Competitive Acid Blocker) drugs for gastric acid-related diseases such as erosive GERD and gastric ulcers, and PARP/tankyrase dual-targeting inhibitors for oncology indications including pancreatic cancer. The company markets JAQBO (Zastaprazan citrate) tablets in South Korea and licenses drug candidates to international pharmaceutical partners.

Product overview

Onconic Therapeutics is a Korean biopharmaceutical company specializing in the research and development of innovative cancer treatments and gastrointestinal therapies. The company has two marketed products: JAQBO tablet 20mg (film-coated) and JAQBO orally disintegrating tablet 20mg, both containing Zastaprazan citrate as a next-generation P-CAB for treatment of erosive GERD and gastric ulcer. The pipeline includes OCN-201 (JPI-547), a second-generation PARP/tankyrase dual inhibitor for cancer treatment, and Zastaprazan (OCN-101) as the core P-CAB technology platform. The company aims for accelerated global new drug approval and commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• JAQBO: JAQBO tablet 20mg (Zastaprazan citrate) - Product brand for gastric acid related disease treatment including erosive GERD and gastric ulcer.
• OCN-201 (JPI-547)
• Zastaprazan (OCN-101/JP-1366)

Products and services

• JAQBO tablet 20mg (Zastaprazan citrate) Pink, round, film-coated tablet containing Zastaprazan citrate 20mg for treatment of erosive gastroesophageal reflux disease (GERD) and gastric ulcer, administered orally once daily for 4-8 weeks.
• JAQBO orally disintegrating tablet 20mg (Zastaprazan citrate) White, round, orally disintegrating tablet containing Zastaprazan citrate 20mg, placed on the tongue and allowed to dissolve in saliva, or taken with water, for treatment of erosive GERD and gastric ulcer.
• OCN-201 (JPI-547) Second-generation PARP inhibitor with PARP/tankyrase dual target mechanism offering better anti-tumor activity compared to approved PARP inhibitors. Received FDA orphan drug designation for pancreatic cancer.
• Zastaprazan (OCN-101/JP-1366) Next-generation P-CAB (Potassium-Competitive Acid Blocker) platform asset for gastric acid related diseases, serving as the active pharmaceutical ingredient underlying the JAQBO commercial brand.

Quantifiable outcome

• FDA orphan drug designation received for PARP/TNKS inhibitor for pancreatic cancer treatment
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered major and minor.

• Chinese Pharmaceutical PartnermajorStrategic or Co-development Partner · 1 June 2026Onconic Therapeutics licensed out GERD drug candidate (Zastaprazan) to China for $127.5 million, representing a significant international licensing deal for their P-CAB technology. The deal structure included upfront and milestone payments.
• BIO USA 2026 ParticipantsminorStrategic or Co-development Partner · 1 June 2026Onconic Therapeutics participated at BIO USA 2026 in San Diego (June 22-25) seeking licensing and partnership opportunities based on recent clinical and preclinical data, alongside other Korean biotech firms including Genome & Company and Oscotec.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Genome & Company: Korean clinical-stage biotech focused on immuno-oncology, participating alongside Onconic at BIO USA 2026. Comparable as a peer Korean biotech pursuing global licensing partnerships from a similar development stage and Asian base.
• Crystal Genomics: Korean clinical-stage biotech developing novel therapeutics, where Onconic's CSO Hyunju Cha previously served as Principal Researcher. Comparable as a Korean biotech with similar drug development capabilities and clinical-stage pipeline orientation.
• Oscotec: Korean clinical-stage biotech participating alongside Onconic at BIO USA 2026 seeking licensing partnerships. Comparable as a similarly-sized Korean biotech pursuing the same global partnering strategy with clinical-stage assets.

Broad incumbents

• AstraZeneca: Develops and commercializes Lynparza (olaparib), the leading approved PARP inhibitor for multiple oncology indications. Comparable as a major oncology player with an established PARP franchise that Onconic's PARP/tankyrase inhibitor must differentiate against.
• GSK: Markets Zejula (niraparib), an approved PARP inhibitor for ovarian and other cancers. Comparable as a major PARP inhibitor competitor that Onconic's PARP/tankyrase dual inhibitor must differentiate against in oncology.
• Takeda Pharmaceutical: Global pharmaceutical company whose vonoprazan (Takecab) is the first and leading approved P-CAB for acid-related diseases. Directly comparable as the established P-CAB market leader against which Onconic's Zastaprazan must compete.
• Pfizer: Markets Talzenna (talazoparib), an approved PARP inhibitor for BRCA-mutated cancers. Comparable as a major oncology incumbent with an established PARP franchise in Onconic's target oncology space.

Regional players

• Hanmi Pharmaceutical: Major Korean pharmaceutical company where CEO John Kim previously served as Executive Director of Clinical Development. Comparable as a Korean pharma with R&D and licensing focus targeting both domestic and global markets.
• Yuhan Corporation: Major Korean pharmaceutical company with both innovative drug development and branded generics businesses. Comparable as a Korean pharma with branded/innovative drug pipeline focus including GI and other specialty therapeutics.
• Daewoong Pharmaceutical: Leading Korean pharmaceutical company with significant GI franchise (including GERD treatments like fexuprazan, a competing P-CAB). Directly comparable as a Korean competitor developing P-CAB therapies for the same GI indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/onconic-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Onconic Therapeutics